Navigation Links
ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study
Date:4/15/2008

rug.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates primarily for the treatment of cancer and infectious disease. The Company seeks to improve the performance and commercial potential of existing treatments by addressing problems associated with these treatment regimens. More information can be found on ADVENTRX's web site at http://www.adventrx.com.

Forward Looking Statement

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk the FDA will determine that ANX-530 and Navelbine are not bioequivalent, including as a result of performing pharmacokinetic equivalence analysis based a patient population other than the population on which ADVENTRX based its analysis; the risk of investigator bias in reporting adverse events as a result of the study's open-label nature, including bias that increased the reporting of adverse events associated with Navelbine and/or that decreased the reporting of adverse events associated with ANX-530; difficulties or delays in manufacturing, marketing and obtaining regulatory approval for ANX-530, including validating commercial manufacturers and suppliers and the potential for automatic injunctions regarding FDA approval of ANX-530 and other challenges by patent holders during the Section 505(b)(2) process; the risk that ADVENTRX will be unable to raise sufficient capital to fund the projects necessary to meet its goals, including funding the c
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting
2. Complete ANX-530 Safety Data to be Published in the 2008 Proceedings of the American Society of Clinical Oncology
3. Elekta Demonstrates Commitment to Stereotactic Innovation at EANS
4. ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
5. Recent Study Confirms Alimentary Healths Bifantis(R) Demonstrates Efficacy in the Treatment of Irritable Bowel Syndrome
6. Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder
7. ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients
8. Magnifi Group Demonstrates Industrys First Interactive Educational Program (IEP) for Spine Fellows
9. Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
10. Job-related stress: NIST demonstrates fatigue effects in silicon
11. USGI Medical Demonstrates First System for Gastrotomy Closure in NOTES
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)...  Having the right people at the table for ... growth and achieving clinical and operational goals. The 22 ... July 20-22, 2014, in San Diego ... healthcare experts discussing how partnerships have positively impacted their ... Chief Executive Officer of Cape Regional Medical Center located ...
(Date:7/23/2014)... La Jolla, CA (PRWEB) July 23, 2014 ... adipose stem cell therapy in the US aimed at ... today announced their newest clinical study for Parkinson’s disease. ... and efficacy of stem cell therapy are paramount when ... , This clinical study makes stem cell therapy accessible ...
(Date:7/23/2014)... July 23, 2014 DuPont Pioneer announced ... as vice president of Agricultural Biotechnology (ABT), effective July ... he served most recently as president, chief executive officer ... business leadership in the seed and crop protection industry ... Paul E. Schickler , president of DuPont Pioneer. “I ...
(Date:7/23/2014)... regulated information -- UCB today announced an ... with positive topline results from the latest Phase ... designed to evaluate the efficacy and safety of ... titration) compared to placebo, as adjunctive treatment in ... fully controlled despite treatment with one or two ...
Breaking Biology Technology:MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7
... -- Olympus Capital Holdings Asia and,its co-investors today ... Arysta LifeScience Corporation, the world,s largest privately held,crop- ... of,approximately JPY 250 billion (US$2.2 billion). The sale ... leading middle market private,equity firm with investment teams ...
... BRISBANE, Australia and SEATTLE, Oct. 20 ,Implicit Bioscience ... US$16.34,million (AU$18.2million) contract payable over 37 months from ... develop its clinical stage,drug oglufanide disodium as a ... of intracellularbacterial diseases. Among these diseases is ...
... by James Cornelius, CEO of Bristol-Myers Squibb, ... Bulletin Board: PMQC, PMQCU, PMQCW) announced today that ... in Long Beach, New,York, will be presenting at ... on Tuesday, October 23 in New York, NY. ...
Cached Biology Technology:Olympus Capital Announces Agreement to Sell Arysta LifeScience Corporation 2Olympus Capital Announces Agreement to Sell Arysta LifeScience Corporation 3Implicit Awarded US $16.3 Million U.S. Government Contract to Develop Immunomodulatory Drug for Biodefense Threats 2Chem Rx to Present at the Paramount BioSciences Healthcare Conference 2Chem Rx to Present at the Paramount BioSciences Healthcare Conference 3Chem Rx to Present at the Paramount BioSciences Healthcare Conference 4
(Date:7/23/2014)... release is available in German . ... stability to cells, drive metabolic processes and transmit signals. ... three-dimensional shapes. Scientists at the Max Planck Institute for ... can be constructed of similar amino acid chains even ... the proteins that exist today arose from common precursors. ...
(Date:7/23/2014)... The Worldwide Innovative Networking in personalized cancer medicine, ... Cancer Center at Thomas Jefferson University will ... only member of this prestigious group in the Tri-State ... delivery of innovative personalized medicine to the patient by ... advocacy. , "Our participation in the WIN consortium means ...
(Date:7/23/2014)... As local and national governments struggle to deal with ... now refining the picture of just how much there ... the ACS journal Environmental Science & Technology , ... that developed countries discard floods into just seven developing ... people who live there. , Knut Breivik and colleagues ...
Breaking Biology News(10 mins):Protein evolution follows a modular principle 2New partnership brings more personalized cancer treatment to Philadelphia 2
... is capitalizing on the potential of two distinct cell ... new study reports. The Northwestern Medicine research, ... Proceedings of the National Academy of Sciences by ... urology at Northwestern University Feinberg School of Medicine ...
... The National Center for Supercomputing Applications (NCSA) has gifted ... shared memory supercomputer named Ember. Originally funded by the ... Computing (HPCBio) group. "We,ve been using Ember for ... genomics," said Victor Jongeneel, Director of HPCBio. "It can ...
... encoded in our DNA but not translated into proteinare key ... say researchers at The Wistar Institute. These non-coding RNA-activators (ncRNA-a) ... during early embryonic development, researchers say, and have also been ... In an online article of the journal ...
Cached Biology News:Bone marrow cells used in bladder regeneration 2New supercomputer to aid genomics research 2'Activating' RNA takes DNA on a loop through time and space 2'Activating' RNA takes DNA on a loop through time and space 3
... microPET R4 is the lowest priced, full ... the world. Despite the microPET R4 ... systems in all performance categories; count rate ... set., microPET is a dedicated small animal ...
... to significantly increase the shelf life of ... increased at room temperature storage conditions in ... is subjected to 0.45 micron filtration, and ... formulation insures consistently high levels of activity ...
... 220 utilizes utilizies CTI Molecular Imaging's ... superior resolution, sensitivty, and a large ... the flexibility to image multiple mice ... microPET is a dedicated small animal ...
... This product has been developed to significantly ... labeled proteins. Stability is increased at ... 2-8 centigrade. This product is subjected ... mercury or azide. This formulation insures ...
Biology Products: